RxDoctor Payments Data

James Ensor, MD

Internal Medicine · Germantown, TNNPI 1205811247

Payments from drug & device makers

$10,315in general payments, 2019–2025

Across 462 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$1K
  • AstraZeneca$916
  • Merck$787
  • AbbVie$712
  • Novartis$646
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,266100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,315 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$81,769
Medicare patients
120
Services billed
4,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$83,937
MounjaroTirzepatide76$75,200
OtezlaApremilast12$54,149
EntrestoSacubitril/Valsartan49$37,723
EliquisApixaban49$34,660
JardianceEmpagliflozin22$24,355
RybelsusSemaglutide18$20,704
RexultiBrexpiprazole15$19,626
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,026
OxycontinOxycodone Hcl13$9,334
KerendiaFinerenone12$8,737
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen226$8,509
Atrovent HfaIpratropium Bromide14$8,442
MyrbetriqMirabegron17$7,500
VascepaIcosapent Ethyl25$7,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,485$104,64185 claims
Lilly USA, LLCMounjaro$574$75,20076 claims
AmgenOtezla$1,080$54,14912 claims
NovartisEntresto$646$37,72349 claims
PfizerEliquis$109$34,66049 claims
Otsuka America Pharmaceutical, Inc.Rexulti$267$19,62615 claims
AstraZenecaBreztri Aerosphere$916$10,02617 claims
BayerKerendia$109$8,73712 claims
Astellas Pharma US IncMyrbetriq$137$7,50017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →